Merck Serono and Pfizer are to work with the Broad Institute in Cambridge, Massachusetts to undertake genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback